In the review, 18 studies were excluded for the reasons as follows: nine were eliminated because they were neither case–control study or cohort study, four were irrelevant to bone tumor or osteosarcoma or Ewing sarcoma, four studies were not studies on the role of TP53 rs1042522 on patient survival or disease progression, one was not consistent with Hardy–Weinberg equilibrium. Here, TP53 is linked to Ewing sarcoma.